Apellis Investigates Needle Safety Concerns in Eye Disease Drug
Apellis Pharmaceuticals has identified internal structural variations in the needle used to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients. However, the company has not definitively linked the needle to the cases. Despite one additional case of the severe side effect, the overall frequency remains rare, leading to a 30% rise in Apellis shares as investors believe the safety crisis is abating.
